These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 26604805)

  • 21. Delamanid for the treatment of pulmonary multidrug-resistant tuberculosis.
    Thakare R; Soni I; Dasgupta A; Chopra S
    Drugs Today (Barc); 2015 Feb; 51(2):117-23. PubMed ID: 25756067
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Delamanid and bedaquiline to treat multidrug-resistant and extensively drug-resistant tuberculosis in children: a systematic review.
    D'Ambrosio L; Centis R; Tiberi S; Tadolini M; Dalcolmo M; Rendon A; Esposito S; Migliori GB
    J Thorac Dis; 2017 Jul; 9(7):2093-2101. PubMed ID: 28840010
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Management of drug resistantTB in patients with HIV co-infection.
    Pontali E; Sotgiu G; Centis R; D'Ambrosio L; Spanevello A; Migliori GB
    Expert Opin Pharmacother; 2015; 16(18):2737-50. PubMed ID: 26478945
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MIC of Delamanid (OPC-67683) against Mycobacterium tuberculosis Clinical Isolates and a Proposed Critical Concentration.
    Stinson K; Kurepina N; Venter A; Fujiwara M; Kawasaki M; Timm J; Shashkina E; Kreiswirth BN; Liu Y; Matsumoto M; Geiter L
    Antimicrob Agents Chemother; 2016 Jun; 60(6):3316-22. PubMed ID: 26976868
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bedaquiline and delamanid in tuberculosis.
    Esposito S; Bianchini S; Blasi F
    Expert Opin Pharmacother; 2015; 16(15):2319-30. PubMed ID: 26293803
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combined Use of Delamanid and Bedaquiline to Treat Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: A Systematic Review.
    Migliori GB; Pontali E; Sotgiu G; Centis R; D'Ambrosio L; Tiberi S; Tadolini M; Esposito S
    Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28178199
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [EXPERIENCE OF USE OF NEW ANTI-TUBERCULOUS DRUG, DELAMANID IN MULTI- AND EXTENSIVELY DRUG RESISTANT TUBERCULOSIS CASES IN OUR HOSPITAL].
    Okumura M; Yoshiyama T
    Kekkaku; 2016 Nov; 91(11-12):699-702. PubMed ID: 30648372
    [TBL] [Abstract][Full Text] [Related]  

  • 28. OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice.
    Matsumoto M; Hashizume H; Tomishige T; Kawasaki M; Tsubouchi H; Sasaki H; Shimokawa Y; Komatsu M
    PLoS Med; 2006 Nov; 3(11):e466. PubMed ID: 17132069
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of multidrug-resistant pulmonary tuberculosis with delamanid based on Japanese guideline recommendations.
    Okumura M; Yoshiyama T; Ogata H; Kurashima A; Yoshimori K; Ohta K; Kudoh S
    Respir Investig; 2020 Mar; 58(2):110-116. PubMed ID: 31838040
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-effectiveness of adding novel or group 5 interventions to a background regimen for the treatment of multidrug-resistant tuberculosis in Germany.
    Wirth D; Dass R; Hettle R
    BMC Health Serv Res; 2017 Mar; 17(1):182. PubMed ID: 28270207
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical benefit of delamanid (OPC-67683) in the treatment of multidrug-resistant tuberculosis patients in China.
    Zhang Q; Liu Y; Tang S; Sha W; Xiao H
    Cell Biochem Biophys; 2013; 67(3):957-63. PubMed ID: 23546935
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New drugs and perspectives for new anti-tuberculosis regimens.
    Tiberi S; Muñoz-Torrico M; Duarte R; Dalcolmo M; D'Ambrosio L; Migliori GB
    Pulmonology; 2018; 24(2):86-98. PubMed ID: 29487031
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Delamanid: A new armor in combating drug-resistant tuberculosis.
    Xavier AS; Lakshmanan M
    J Pharmacol Pharmacother; 2014 Jul; 5(3):222-4. PubMed ID: 25210407
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Synthetic investigational new drugs for the treatment of tuberculosis.
    Kwon YS; Koh WJ
    Expert Opin Investig Drugs; 2016; 25(2):183-93. PubMed ID: 26576631
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Insights into drug-resistant tuberculosis treatment: results of The Union DR-TB Working Group Survey, 2017.
    Mezwa K; McAnaw S; Chiang CY; Trébucq A; Horsburgh CR
    Public Health Action; 2018 Sep; 8(3):141-144. PubMed ID: 30271731
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Interim outcomes of delamanid for the treatment of MDR- and XDR-TB in South Korea.
    Mok J; Kang H; Hwang SH; Park JS; Kang B; Lee T; Koh WJ; Yim JJ; Jeon D
    J Antimicrob Chemother; 2018 Feb; 73(2):503-508. PubMed ID: 29069496
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Artificial intelligence enabled parabolic response surface platform identifies ultra-rapid near-universal TB drug treatment regimens comprising approved drugs.
    Clemens DL; Lee BY; Silva A; Dillon BJ; Masleša-Galić S; Nava S; Ding X; Ho CM; Horwitz MA
    PLoS One; 2019; 14(5):e0215607. PubMed ID: 31075149
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bedaquiline and delamanid for the treatment of multidrug-resistant tuberculosis: a multicentre cohort study in Korea.
    Kim CT; Kim TO; Shin HJ; Ko YC; Hun Choe Y; Kim HR; Kwon YS
    Eur Respir J; 2018 Mar; 51(3):. PubMed ID: 29545276
    [TBL] [Abstract][Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.